SynthesisAdvances in therapy2026
Comparative Effectiveness and Safety of Fecal Microbiota Transplantation in Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis.
Synthesis in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of Different Types of Pectin Oligosaccharides on the Community Structure and Metabolism of Human Fecal Microbiota.Microorganisms · 2026Article
- Article
- Restoring Microbial Balance: Clinical Applications, Challenges, and Future Directions of Fecal Microbiota Transplantation in Pediatric Disorders.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionFecal microbiota transplantation (FMT) is a potential therapy for ulcerative colitis (UC). Evidence has expanded, but the impact of delivery route on efficacy and safety remains uncertain.
methodsWe systematically searched PubMed, Embase, Cochrane Library, Web of Science and China National Knowledge Infrastructure (CNKI) from inception to October 2025 for randomized controlled trials (RCTs) comparing donor-derived FMT with placebo/sham or autologous FMT in patients with UC. Primary outcomes were clinical and endoscopic remission at induction (8-12 weeks). Adverse events (AEs) were secondary. Random effect models generated risk ratios (RRs) with 95% CIs. Pre-specified subgroup analyses compared delivery routes (colonoscopy, rectal enema, combined colonoscopy + enema, nasoduodenal infusion, oral capsules).
resultsSixteen RCTs were included. Overall, FMT improved clinical remission (RR = 1.81, 95% CI: 1.41-2.31; I
conclusionsFMT improves induction-phase clinical and endoscopic remission in patients with UC without increasing AEs. Efficacy appears route-dependent, with colonoscopy + enema demonstrating the largest effect. Head-to-head trials optimizing route and dosing with longer follow-up are warranted.
Indexed as
Identifiers
41945234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.